Veeva encouraged to tap CRO industry after inVentiv puts head in the cloud

By Dan Stanton

- Last updated on GMT

inVentiv signed a deal to use Veeva's cloud-based clinical trial management software in October
inVentiv signed a deal to use Veeva's cloud-based clinical trial management software in October

Related tags Contract research organization

Veeva Systems has reported a robust Q3 strengthened by increasing interest in its cloud-based clinical trial management software and a deal with inVentiv Health.

Two years after launching the cloud-based regulated content management system Veeva Vault, the California-based company has announced it has surpassed 100 customers attributing to a 52% jump in sales for the first quarter fiscal year 2015 year-on-year.

Vault hosts a number of tools to assist pharma and biotech, in organising and processing R&D documentation - including cloud-based electronic trial master file (eTMF) and regional submission system for clinical trials, and Vault QualityDocs for managing quality and manufacturing SOPs – but CEO Peter Gassner said having contract research organisations (CROs) on the books is testament of the efficiency of such technology.

“The CROs are important, whether they're growing incrementally or shrinking incrementally, they're doing almost half of the clinical trials on behalf of the life sciences industry,”​ he said. In October inVentiv Health Clinical​ became the first of the top eight CROs to choose Veeva’s clinical product (in this case the eTMF package), and Gassner said this could encourage more key players to come on board. 

“We have about a dozen CRO customers today and each time a CRO chooses Vault, it's kind of extra important because the reason that the CROs exist is to be able to run these trials more efficiently, more cheaply and more quickly than their companies could do themselves,”​ he said. “They make a technology choice [and] that contributes to their competitive advantage.”

Tthe total number of “Vaults”​ utilised by Veeva customers had grown threefold over the past year, and within the past quarter the company added a third Top 10 Pharma client, an emerging biotech, as well as inVentiv.

Technology innovation driving growth

For the three months ending October 31, Veeva reported total sales of $84m (€67m), while net income clocked in at just over $10m, up 57% on the same period last year.

During the call, the firm was asked whether demand and sales were up due to companies with fully depreciated legacy management systems. While Veeva’s President Matt Wallach said this was a continual driver across the industry and for Veeva’s products, Gassner added changing technology was also a key factor.

“I think the momentum is caused by this [cloud-based software] being the first major technology innovation in content management for life sciences [in the past 10-15 years],”​ he said.

“It's the technology innovation that's really driving our growth.”

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more